Hong Kong health authorities have apologised for mistakenly giving pneumococcal vaccines to two children at a health centre ...

Simmons AE, Ximenes R, Gebretekle GB, Salvadori MI, Wong E, Tuite AR. Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults: A systematic review ...

In the past year, shares of Merck have plunged 21.7% compared with the industry’s decrease of 2.6%. Image Source ... to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults aged 18 ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate vaccine (PCV) candidate, VAX-31 with the first subjects now dosed in this ...

The company is also developing a 24-valent pneumococcal vaccine, VAX-24, which is in a phase 2 study in paediatric patients, with results due in the first quarter of 2025.

The Pneu-C-20 vaccine averted an additional 468 (IQR: 436–494) IPD cases, 730 (IQR: 533–976) hospitalized pCAP cases, 16,084 (IQR: 15,082–17,071) outpatient pCAP cases and 109,527 (IQR: ...

Several important lessons should be learnt from the current global struggle to eradicate polio with the use of a vaccine that has been in existence for several decades. The challenges are likely ...

13 release. The phase 3 trial had aimed to enroll 18,500 people aged 60 years and up with a history of urinary tract infection to assess whether the nine-valent vaccine candidate could prevent ...

recommended the approval of CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae ...